Review of four major biomolecular target sites for COVID-19 and possible inhibitors as treatment interventions
Vigbedor et al.
, Review of four major biomolecular target sites for COVID-19 and possible inhibitors as treatment interventions
, Journal of Applied Pharmaceutical Science, doi:10.7324/JAPS.2021.110825 (Review)
Review of major target sites in SARS-CoV-2 and the host organism along with potential inhibitors.
Vigbedor et al., 8 May 2021, peer-reviewed, 8 authors.
Abstract: Journal of Applied Pharmaceutical Science Vol. 11(08), pp 192-196, August, 2021
Available online at http://www.japsonline.com
Review of four major biomolecular target sites for COVID-19 and
possible inhibitors as treatment interventions
Bright Vigbedor1*, Clement Okraku Tettey2, Edward Ken Essuman3, Isaac Kyere4, Albert Aniagyei1, Nii Korley Kortei3,
Adjoa Agyemang Boakye2, Jonathan Osei-Owusu5
Department of Basic Sciences, School of Basic and Biomedical Sciences, University of Health and Allied Sciences, Ho, Ghana, West Africa.
Department of Biomedical Sciences, School of Basic and Biomedical Sciences, University of Health and Allied Sciences, Ho, Ghana, West Africa
Department of Nutrition and Dietetics, School of Allied Health Sciences, University of Health and Allied Sciences, Ho, Ghana, West Africa.
Department of Chemistry, Kwame Nkrumah University of Science and Technology, Ghana.
Department of Biological, Physical and Mathematical Sciences, University of Environment and Sustainable Development, Somanya, Ghana
Received on: 15/01/2021
Accepted on: 12/04/2021
Available online: 05/08/2021
This paper focuses on the review of major target sites in both the host organism and the severe acute respiratory
syndrome coronavirus 2 virus and the inhibitors that have been screened so far to unravel possible treatment agents. In
this review, four major target sites were found to be the main sites where the design of possible inhibitors and treatment
interventions could be probed. The four major sites that were reviewed include main protease, transmembrane
protease, serine 2, RNA-dependent RNA polymerase, and angiotensin-converting enzyme 2. Several existing drug
candidates have been screened as inhibitors of the reviewed target sites and could serve as lead agents, prodrugs,
and prospects for the treatment of coronavirus disease 2019. In this review, several inhibitors such as chloroquine
(CQ) and hydroxychloroquine have gone through the clinical trial phase and are being utilized for the management
of the disease. Drug candidates such as CQ, derivatives, remdesivir, and favipiravir have been used for the treatment
of infected persons with 100% recovery rate. It is, therefore, imperative that further structural activity relationship
and modifications be carried out using these drug candidates as models for synthesizing new analogues as treatment
COVID-19, pandemic, ACE2,
drug, chloroquine, inhibitor.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.